Mankind Pharma Ltd Share Price
As on 04 June 2026 at 20:12 IST
Mankind Pharma Q1 FY26 Results:
Net profit for the period declined 18% to ₹438 crores in Q1 FY26, from ₹536.5 crores in Q1 FY25. Total income for the quarter increased 23% year-on-year to ₹3,650 crores from ₹2,967 crores.
About Mankind Pharma Ltd
Mankind Pharma Ltd is a prominent pharmaceutical company in India, engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations. It operates within the pharmaceutical sector. The company was incorporated in the year 1991 and began its operations in 1995. Over the years, it has grown to become one of the top pharmaceutical companies in India, known for its commitment to quality and affordability. The headquarters of Mankind Pharma is located in New Delhi, India. Mankind Pharma's main products include a wide range of pharmaceuticals and consumer healthcare products. +
The Current prices are delayed, log in for live prices
LOGINOver 1 Month
4.95%
Over 6 Months
7.43%
Over 1 Year
0.73%
Over 3 Years
66.41%
Mankind Pharma Ltd Summary
Close ₹2,369.50
Open ₹2,320
High ₹2,383.50
Low ₹2,285.10
Volume 10,12,891
Net Turnover (in Cr) ₹235.74
52Wk High ₹2,716.50
52Wk Low ₹1,909.70
52Wk High / Low
1,909.70
2,716.50
Mankind Pharma Ltd Fundamentals
Key Financial Data
Market Cap (in Cr) ₹97,838.83
EPS (TTM) 51.39
Book Value (BV) 397.11
Div. Yield -
P/E (TTM) 48.05
Price/Book Value 5.97
Delivery % 51.57 %
Face Value 1
Key Ratios
PE Ratio 51.39
PB Ratio 6.83
EV to Sales 11.26
PEG Ratio 75.21
ROA 8.83
ROE 13.89
Debt-Equity 0.30
Net Profit Margin 17.81
Operating Profit Margin 28.95
Mankind Pharma Ltd Financials
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 12,744.23 | 10,540.66 | 8,878 | 7,977.58 | 6,385.38 |
| Total Expenses | 10,240.14 | 8,157.93 | 7,219.18 | 6,017.43 | 4,705.45 |
| Profit Before Tax | 2,516.33 | 2,397.94 | 1,671.24 | 1,974.60 | 1,691.61 |
| Profit After Tax | 2,006.59 | 1,940.79 | 1,309.68 | 1,452.96 | 1,293.03 |
| Operating Profit After Depreciation | 2,933.50 | 2,415.48 | 1,703.28 | 2,018.76 | 1,700.08 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 19,524.02 | 4,614.65 | 4,302.24 | 3,614.37 | 1,659.28 |
| Total Non Current Assets | 20,771.26 | 5,395.03 | 5,387.58 | 4,740.92 | 2,465.99 |
| Total Current Assets | 6,988.27 | 6,568.22 | 4,327.87 | 4,406.82 | 3,906.64 |
| Total Assets | 27,759.53 | 11,963.25 | 9,715.45 | 9,147.74 | 6,372.63 |
| Total Shareholder's Fund | 14,332.39 | 9,363.09 | 7,435.22 | 6,155.23 | 4,722 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 2,413.38 | 2,152.44 | 1,813.30 | 919.78 | 1,137.24 |
| Net Cash Used In Investing Activities | -12,624.07 | -2,080.52 | -1,051.81 | -1,368.67 | -1,221.84 |
| Net Cash Used In Financing Activities | 10,232.56 | 5.27 | -739.73 | 604.62 | -7.81 |
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 9,991.01 | 8,899.75 | 8,289.94 | 7,690.04 | 5,677.68 |
| Total Expenses | 7,685.02 | 6,714.55 | 6,727.10 | 5,818.60 | 4,237.47 |
| Profit Before Tax | 2,305.99 | 2,185.20 | 1,562.84 | 1,871.44 | 1,440.21 |
| Profit After Tax | 1,884.25 | 1,772.63 | 1,248.26 | 1,389.42 | 1,084.37 |
| Operating Profit After Depreciation | 2,677.75 | 2,201.53 | 1,590.58 | 1,918.56 | 1,448.19 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 3,486.82 | 3,620.98 | 3,193.85 | 2,952.58 | 982.01 |
| Total Non Current Assets | 19,132.31 | 5,886.84 | 5,854.21 | 5,122.99 | 2,790.35 |
| Total Current Assets | 4,696.01 | 5,629.55 | 3,516.91 | 3,815.71 | 3,089.98 |
| Total Assets | 23,828.32 | 11,516.39 | 9,371.12 | 8,938.70 | 5,880.33 |
| Total Shareholder's Fund | 14,640.27 | 9,702.77 | 7,783.91 | 6,540.45 | 4,734.27 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 2,322.16 | 1,736.08 | 1,798.99 | 821.44 | 1,022.33 |
| Net Cash Used In Investing Activities | -12,178.83 | -1,665.19 | -1,040.61 | -1,360.27 | -1,127.16 |
| Net Cash Used In Financing Activities | 9,845.34 | -4.73 | -710.41 | 578.63 | 88.87 |
| Particulars (in ₹ Cr.) | 2026-03 | 2025-12 | 2025-09 | 2025-06 | 2025-03 |
|---|---|---|---|---|---|
| Total Revenue | 3,442.93 | 3,567.20 | 3,697.16 | 3,570.35 | 3,079.37 |
| Total Expenses | 2,513.05 | 2,647.77 | 2,775.83 | 2,723.58 | 2,400.52 |
| Profit Before Tax | 659.17 | 509 | 624.02 | 540.49 | 511.09 |
| Profit After Tax | 559.42 | 413.88 | 520.18 | 444.62 | 424.65 |
| Operating Profit after Depreciation | 1,047.16 | 995.39 | 1,015.52 | 929.82 | 932.50 |
| Particulars (in ₹ Cr.) | 2026-03 | 2025-12 | 2025-09 | 2025-06 | 2025-03 |
|---|---|---|---|---|---|
| Total Revenue | 2,581.82 | 2,632.68 | 2,608.78 | 2,541.36 | 2,119.46 |
| Total Expenses | 1,662.98 | 1,854.43 | 1,915.59 | 1,868.29 | 1,777.62 |
| Profit Before Tax | 788.01 | 505.29 | 524.63 | 493.66 | 284.45 |
| Profit After Tax | 713.61 | 448.88 | 458.90 | 412.76 | 238.16 |
| Operating Profit after Depreciation | 1,045.54 | 834.77 | 770.86 | 737.29 | 561.35 |
Mankind Pharma Ltd Technicals
Support and Resistance
S3 S2 S1 Pivot R1 R2 R3
S1 2,308.57
S2 2,247.63
S3 2,210.17
Pivot 2,346.03
R1 2,406.97
R2 2,444.43
R3 2,505.37
Moving Average
20 SMA 2,430.95
50 SMA 2,242.44
100 SMA 2,192.43
200 SMA 2,285.84
Mankind Pharma Ltd Corporate Actions
Mankind Pharma Ltd
₹1.0/Share
Announcement Date 08 Aug 2025
Record Date 08 Aug 2025
Div Yield 100%
Mankind Pharma Ltd Peer Comparison
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,789.45 | ₹4,29,349 |
| Divis Laboratories Ltd | ₹6,574.90 | ₹1,74,542.94 |
| Torrent Pharmaceuticals Ltd | ₹4,369.50 | ₹1,47,883.74 |
| Cipla Ltd | ₹1,375.05 | ₹1,11,076.61 |
| Zydus Lifesciences Ltd | ₹1,076.45 | ₹1,08,316.06 |
Mankind Pharma Ltd Top Mutal Funds Invested
| Fund Name | AUM |
|---|---|
| ICICI Pru P.H.D Fund | 7.58% |
| Franklin India Opportunities Fund | 3.24% |
| Nippon India Pharma Fund | 3.04% |
| SBI Large Cap Fund | 1.71% |
| HDFC Large Cap Fund | 1.61% |
Mankind Pharma Ltd News
Mankind Pharma Ltd eases for fifth straight session
Mankind Pharma Ltd is quoting at Rs 2412.2, down 0.47% on the day as on 13:19 IST on the NSE. The stock tumbled 2.88% in last one year as compared to a 3.49% slide in NIFTY and a 15.46% spurt in the Nifty Pharma index.
27 May 2026, 01:35 pm
Mankind Pharma allots 80.872 equity shares under ESOP
20 May 2026, 09:34 am
Mankind Pharma Ltd rises for third straight session
Mankind Pharma Ltd is quoting at Rs 2511.4, up 2% on the day as on 12:49 IST on the NSE. The stock is down 2.38% in last one year as compared to a 4.94% slide in NIFTY and a 13.93% slide in the Nifty Pharma index.
15 May 2026, 01:05 pm
Mankind Pharma Ltd up for fifth session
Mankind Pharma Ltd is quoting at Rs 2439.2, up 2.69% on the day as on 12:44 IST on the NSE. The stock is up 1.29% in last one year as compared to a 0.65% spurt in NIFTY and a 14.52% spurt in the Nifty Pharma.
08 May 2026, 01:00 pm
Mankind Pharma to table results
On 19 May 2026
08 May 2026, 11:45 am
Mankind Pharma Ltd Stock Analysis
- Annual revenue for Mankind Pharma Ltd increased by 12.26% to ₹9,991.01 crore in FY 2025 from ₹8,899.75 crore in FY 2024.
- Annual Net Profit for Mankind Pharma Ltd increased by 6.30% to ₹1,884.25 crore in FY 2025 from ₹1,772.63 crore in FY 2024.
- Promoter Shareholding in Mankind Pharma Ltd decreased by 0.01% in the most recent quarter, from 72.66% in December 2025 to 72.66% in March 2026.
- Mankind Pharma Ltd delivered a 1-year return of 0.73% compared to the Nifty 50, which provided a return of -4.63% as of the last trading session.
- Mankind Pharma Ltd share price moved down by 0.69% from its previous close of INR ₹2,369.50. The latest Mankind Pharma Ltd share price is INR ₹2,353.20.
- Mankind Pharma Ltd share price today has been at a low of 2,343.80 and a high of 2,379.60. Over the past 52 weeks, the Mankind Pharma Ltd share price has seen a low of 1,909.70 and a high of 2,716.50.
About Mankind Pharma Ltd
Mankind Pharma Ltd is a prominent pharmaceutical company in India. It is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations. The company operates in various therapeutic areas, including antibiotics and erectile dysfunction medications. Additionally, Mankind Pharma has a strong presence in the consumer healthcare segment. Its products include condoms, pregnancy detection kits, and emergency contraceptives.
Mankind Pharma falls under the pharmaceutical sector. The company was incorporated in 1991 and began its operations in 1995. Over the years, it has grown to become one of the top pharmaceutical companies in India, known for its commitment to quality and affordability.
The headquarters of Mankind Pharma is located in Okhla Phase III, New Delhi, India. The promoters of the company include Ramesh Juneja Family Trust, with a 20.80% stake. A team of managerial promoters manage the operations of the company. They are
Mankind Pharma is a leading player in the pharmaceutical industry. Still, it is not the largest in terms of market share or capitalization. However, it is recognized for its strong market presence and innovative products. The company has a market capitalization of approximately ₹1.082 trillion. This makes it one of the most valuable pharmaceutical companies in India. The registered office of Mankind Pharma Ltd is in Okhla Industrial Estate, New Delhi. Meanwhile the office of the registrars is in Hyderabad, Telangana.
The company aims to provide cost-effective pharmaceutical products that improve the lives of patients. Mankind Pharma focuses on innovation to develop superior-quality medications. This commitment to innovation allows the company to meet the growing needs of society. It also helps provide solutions for various health challenges.
Mankind Pharma's vision includes a strong emphasis on quality. The company believes that maintaining high standards of quality is essential for building trust with its customers. This focus on quality is reflected in every aspect of the company's operations, from research and development to manufacturing and distribution. Mankind Pharma strives to deliver products that meet the highest standards of safety and efficacy.
Accessibility is another key component of Mankind Pharma's vision. The company aims to make its products available across different geographic regions. This includes expanding its presence in rural and underserved areas where access to healthcare is often limited. Mankind Pharma believes that making its products widely available can help bridge the gap in healthcare access. This, in turn, can improve the overall health of communities.
The company's vision also includes a commitment to sustainability. Mankind Pharma is dedicated to operating in an environmentally responsible manner. This includes implementing sustainable business practices and supporting initiatives that promote environmental conservation.
Mankind Pharma's vision is supported by a strong corporate culture that values integrity and accountability. The company believes that adhering to these principles is essential for building trust with its customers and stakeholders. This trust is crucial for achieving the company's long-term goals and sustaining its growth.
The company also places a strong emphasis on customer-centricity. Mankind Pharma strives to understand the needs of its customers and provide personalized solutions. This customer-centric approach enables the company to build strong relationships with its customers. It also helps deliver products that meet their specific needs.
Mankind Pharma's vision includes a focus on continuous improvement. The company is committed to constantly enhancing its products and services. This includes investing in research and development to develop new and innovative solutions.
The company's vision is also aligned with its mission to improve the quality of life for patients. Mankind Pharma aims to provide medications that help people lead healthier lives. This includes developing treatments for various acute and chronic conditions. The company believes that improving the health of individuals can have a positive impact on society as a whole.
Mankind Pharma's vision extends beyond its products and services. The company is actively involved in corporate social responsibility (CSR) initiatives. These initiatives focus on areas such as health, education, and community development. Mankind Pharma believes that giving back to society is an important part of its vision and mission.
The company's vision is also reflected in its strategic priorities. These include expanding its global presence and improving its operational efficiency. Mankind Pharma aims to achieve these goals by leveraging its strengths and capitalizing on opportunities in the market.
A dedicated team of professionals supports Mankind Pharma's vision. The company's employees are committed to achieving its vision and mission. Mankind Pharma believes that investing in its people is essential for driving innovation and achieving its strategic objectives.
Mankind Pharma falls under the pharmaceutical sector. The company was incorporated in 1991 and began its operations in 1995. Over the years, it has grown to become one of the top pharmaceutical companies in India, known for its commitment to quality and affordability.
The headquarters of Mankind Pharma is located in Okhla Phase III, New Delhi, India. The promoters of the company include Ramesh Juneja Family Trust, with a 20.80% stake. A team of managerial promoters manage the operations of the company. They are
- Rajeev Juneja
- Sheetal Arora
- Satish Kumar Sharma
- Vivek Kalra
Mankind Pharma is a leading player in the pharmaceutical industry. Still, it is not the largest in terms of market share or capitalization. However, it is recognized for its strong market presence and innovative products. The company has a market capitalization of approximately ₹1.082 trillion. This makes it one of the most valuable pharmaceutical companies in India. The registered office of Mankind Pharma Ltd is in Okhla Industrial Estate, New Delhi. Meanwhile the office of the registrars is in Hyderabad, Telangana.
The vision of Mankind Pharma Limited
Mankind Pharma Ltd envisions a future where high-quality healthcare is accessible and affordable to all. The company's vision is to become a global pharmaceutical leader. It aims to be admired for its commitment to the affordability and accessibility of its products.The company aims to provide cost-effective pharmaceutical products that improve the lives of patients. Mankind Pharma focuses on innovation to develop superior-quality medications. This commitment to innovation allows the company to meet the growing needs of society. It also helps provide solutions for various health challenges.
Mankind Pharma's vision includes a strong emphasis on quality. The company believes that maintaining high standards of quality is essential for building trust with its customers. This focus on quality is reflected in every aspect of the company's operations, from research and development to manufacturing and distribution. Mankind Pharma strives to deliver products that meet the highest standards of safety and efficacy.
Accessibility is another key component of Mankind Pharma's vision. The company aims to make its products available across different geographic regions. This includes expanding its presence in rural and underserved areas where access to healthcare is often limited. Mankind Pharma believes that making its products widely available can help bridge the gap in healthcare access. This, in turn, can improve the overall health of communities.
The company's vision also includes a commitment to sustainability. Mankind Pharma is dedicated to operating in an environmentally responsible manner. This includes implementing sustainable business practices and supporting initiatives that promote environmental conservation.
Mankind Pharma's vision is supported by a strong corporate culture that values integrity and accountability. The company believes that adhering to these principles is essential for building trust with its customers and stakeholders. This trust is crucial for achieving the company's long-term goals and sustaining its growth.
The company also places a strong emphasis on customer-centricity. Mankind Pharma strives to understand the needs of its customers and provide personalized solutions. This customer-centric approach enables the company to build strong relationships with its customers. It also helps deliver products that meet their specific needs.
Mankind Pharma's vision includes a focus on continuous improvement. The company is committed to constantly enhancing its products and services. This includes investing in research and development to develop new and innovative solutions.
The company's vision is also aligned with its mission to improve the quality of life for patients. Mankind Pharma aims to provide medications that help people lead healthier lives. This includes developing treatments for various acute and chronic conditions. The company believes that improving the health of individuals can have a positive impact on society as a whole.
Mankind Pharma's vision extends beyond its products and services. The company is actively involved in corporate social responsibility (CSR) initiatives. These initiatives focus on areas such as health, education, and community development. Mankind Pharma believes that giving back to society is an important part of its vision and mission.
The company's vision is also reflected in its strategic priorities. These include expanding its global presence and improving its operational efficiency. Mankind Pharma aims to achieve these goals by leveraging its strengths and capitalizing on opportunities in the market.
A dedicated team of professionals supports Mankind Pharma's vision. The company's employees are committed to achieving its vision and mission. Mankind Pharma believes that investing in its people is essential for driving innovation and achieving its strategic objectives.
FAQ’s
What is the share price of Mankind Pharma Ltd today?
Mankind Pharma Ltd share price as on 4 Jun 2026 is ₹ 2353.2
What is the Market Cap of Mankind Pharma Ltd?
The market cap of Mankind Pharma Ltd stock is ₹97,838.83 Cr.
What is the PE Ratio of Mankind Pharma Ltd?
The Price to Earnings (P/E) Ratio of Mankind Pharma Ltd is 51.39
What is the PB Ratio of Mankind Pharma Ltd?
The Price to Book (P/B) Ratio of Mankind Pharma Ltd is 6.83
What is the 52 week high of Mankind Pharma Ltd Share Price?
The 52 week high of Mankind Pharma Ltd share price stands at ₹2,716.50
What is the 52 week low of Mankind Pharma Ltd Share Price?
The 52 week low of Mankind Pharma Ltd share price stands at ₹1,909.70
How can I buy shares of Mankind Pharma Ltd?
Simply open a demat account with Torus Digital and place an order to buy shares of Mankind Pharma Ltd.
Open FREE
3-in-1 Account
for all your banking, trading and demat needs
Trade in stocks,
derivatives and F&O
